Stroke: Covidien battles "failed" clot-removing device study

February 8, 2013 by MassDevice staff

Medical device company Covidien releases 2-year study results combating a government-funded study that questioned the benefit of medical device intervention in stroke patient's future independence.

Covidien's Solitaire FR revascularization device

Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.